Company profile

Mark J. Alles
Fiscal year end
IRS number

CELG stock data



31 Oct 19
22 Sep 20
31 Dec 20


Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
9 Jul 20 Celgene Common Stock Sell Dispose S No 102.28 2,241 229.21K 7,008,510
9 Jul 20 Celgene Common Stock Aquire X No 5.88 38,979 229.2K 7,010,751
9 Jul 20 Celgene Option Warrant Common Stock, $0.001 par value Dispose X No 5.88 38,979 229.2K 0
1 Jul 20 Celgene Common Stock Buy Aquire P No 92.5 108,108 10M 6,971,772
20 Nov 19 Rupert Vessey Common Stock Sale back to company Dispose D No 0 613 0 0
20 Nov 19 Rupert Vessey Common Stock Sale back to company Dispose D No 0 60,927 0 0
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A No 0 24,209 0 60,927
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A No 0 13,906 0 36,718
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A No 0 8,634 0 22,812
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D No 0 37,660 0 0
13F holders
Current Prev Q Change
Total holders 5 8 -37.5%
Opened positions 4 7 -42.9%
Closed positions 7 11 -36.4%
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 1.31M 14.84M -91.1%
Total shares 13.71K 137.26K -90.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
TCF National Bank 6.94K $641K NEW
Stellar Capital Management 6.63K $658K NEW
Filbrandt Wealth Management 125 $14K NEW
Orion Portfolio Solutions 19 $0 NEW
IFP Advisors 0 $0
Largest transactions
Shares Bought/sold Change
Central Bank & Trust 0 -47.14K EXIT
Osborn Williams & Donohoe 0 -40.41K EXIT
Thomasville National Bank 0 -38.16K EXIT
Headinvest 0 -11.3K EXIT
TCF National Bank 6.94K +6.94K NEW
Stellar Capital Management 6.63K +6.63K NEW
Perennial Advisors 0 -235 EXIT
Filbrandt Wealth Management 125 +125 NEW
Elmwood Wealth Management 0 -20 EXIT
Orion Portfolio Solutions 19 +19 NEW

Financial report summary

  • Our operating results may be subject to significant fluctuations.
  • Our future commercial success depends on gaining regulatory approval for products in development, and obtaining approvals for our current products for additional indications.
  • If we fail to comply with laws or government regulations or policies our business could be adversely affected.
  • Sales of our products will be significantly reduced if access to and reimbursement for our products by governmental and other third-party payers are reduced or terminated.
  • Federal and state legislation may affect our pricing policies and government reimbursement of our products which may adversely impact our revenues and profitability.
  • Our ability to sell our products to hospitals in the United States depends in part on our relationships with group purchasing organizations.
  • Our products may face competition from lower cost generic or follow-on products.
  • Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor (CAR) T cell therapy, may present significant challenges and risks for us.
  • Our business operates in an extremely competitive environment.
  • A decline in general economic conditions would adversely affect our results of operations.
  • We may be required to modify our business practices, pay fines and significant expenses or experience other losses due to governmental investigations or other enforcement activities.
  • The development of new biopharmaceutical products involves a lengthy and complex process and we may be unable to commercialize any of the products we are currently developing.
  • Disruptions of our manufacturing and distribution operations could significantly interrupt our production and distribution capabilities.
  • The consolidation of drug wholesalers and other wholesaler actions could increase competitive and pricing pressures.
  • Risks from the improper conduct of employees, agents, contractors or collaborators could adversely affect our business or reputation.
  • We are subject to a variety of risks related to the conduct and expansion of our business internationally, particularly in emerging markets.
  • We may not realize the anticipated benefits of acquisitions and strategic initiatives.
  • We may not be able to continue to attract and retain highly qualified managerial, scientific, manufacturing and commercial talent.
  • Risks associated with using hazardous materials in our business could subject us to significant liability.
  • We are subject to various legal proceedings, claims and investigative demands in the ordinary course of our business, the ultimate outcome of which may result in significant expense, payments and penalties.
  • Product liability claims could adversely affect our business, results of operations and financial condition.
  • Changes in our effective income tax rate could adversely affect our results of operations.
  • Currency fluctuations and changes in exchange rates could adversely affect our revenue growth, increase our costs and cause our profitability to decline.
  • We may experience an adverse market reaction if we are unable to meet our financial reporting obligations.
  • Impairment charges or write downs in our books and changes in accounting standards could have a significant adverse effect on our results of operations and financial condition.
  • The price of our common stock may fluctuate significantly.
  • Our business would be adversely affected if we are unable to service our debt obligations.
  • A breakdown or breach of our information technology systems and cyber security efforts could subject us to liability, reputational damage or interrupt the operation of our business.
  • The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.
  • We have certain charter and by-law provisions that may deter a third party from acquiring us and may impede the stockholders’ ability to remove and replace our management or board of directors.
  • In addition to the risks relating to our common stock, holders of our CVRs are subject to additional risks.
  • While the merger is pending, we are subject to business uncertainties and contractual restrictions that could materially adversely affect our operating results, financial position and/or cash flows or result in a loss of employees, customers, collaborators or suppliers.
  • Lawsuits have been filed against us and Bristol-Myers Squibb and other lawsuits may be filed against us and/or Bristol-Myers Squibb challenging the transactions contemplated by the merger agreement. An adverse ruling in any such lawsuit may delay or prevent the proposed acquisition from being completed.
  • We may have difficulty attracting, motivating and retaining executives and other key employees in light of the merger.
Content analysis ?
H.S. freshman Avg
New words: antibody, apremilast, banc, checkpoint, CMA, deadline, divest, en, Inducible, INREBIC, Jounce, macrophage, MF, NaN, pool, QUAZAR, retroactive, SPARC, TSA
Removed: ADR, argued, breast, certify, content, create, curiae, denying, dispute, entity, exact, implemented, interlocutory, led, outpatient, prohibition, protecting, resolution, Sherman, submission, Synthon, thirteen


Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
22 Sep 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate.
17 Sep 20
Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
Methods of synthesis of (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
15 Sep 20
Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Methods of treating vitiligo using PD-1 binding antibodies
8 Sep 20
Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Methods Using 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE for Treatment of Intermediate Lymphocytic Lymphoma
3 Sep 20
Methods of treating, preventing or managing mantle cell lymphomas are disclosed.